US20060183129A1 - Characterization of the I-SpomI endonuclease from fission yeast - Google Patents

Characterization of the I-SpomI endonuclease from fission yeast Download PDF

Info

Publication number
US20060183129A1
US20060183129A1 US10/933,476 US93347604A US2006183129A1 US 20060183129 A1 US20060183129 A1 US 20060183129A1 US 93347604 A US93347604 A US 93347604A US 2006183129 A1 US2006183129 A1 US 2006183129A1
Authority
US
United States
Prior art keywords
spomi
cell
dna
site
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/933,476
Other languages
English (en)
Inventor
Stefan Pellenz
Bernard Dujon
Alexis Harington
Bernd Schafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Institut Pasteur de Lille
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/933,476 priority Critical patent/US20060183129A1/en
Priority to US11/250,633 priority patent/US7732194B2/en
Publication of US20060183129A1 publication Critical patent/US20060183129A1/en
Assigned to UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR reassignment UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES), PELLENZ, STEFAN, SCHAFER, BERND, DUJON, BERNARD
Priority to US12/689,513 priority patent/US8173429B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Definitions

  • This invention relates to a nucleotide sequence that encodes the restriction endonuclease I-SpomI and a nucleotide sequence that corresponds to an I-SpomI restriction site.
  • This invention also relates to vectors containing the nucleotide sequences, cells transformed with the vectors, transgenic organisms based on the vectors, and cell lines derived from cells in the organisms.
  • This invention also relates to the use of I-SpomI for mapping eukaryotic genomes and for in vivo site directed genetic recombination.
  • Transgenic mammals have provided a means for studying gene regulation during embryogenesis and in differentiation, for studying the action of genes, and for studying the intricate interaction of cells in the immune system.
  • the whole animal is the ultimate assay system for manipulated genes, which direct complex biological processes.
  • Transgenic animals can provide a general assay for functionally dissecting DNA sequences responsible for tissue specific or developmental regulation of a variety of genes.
  • transgenic animals provide useful vehicles for expressing recombinant proteins and for generating precise animal models of human genetic disorders.
  • Transgenic lines which have a predisposition to specific diseases and genetic disorders, are of great value in the investigation of the events leading to these states. It is well known that the efficacy of treatment of a genetic disorder may be dependent on identification of the gene defect that is the primary cause of the disorder. The discovery of effective treatments can be expedited by providing an animal model that will lead to the disease or disorder, which will enable the study of the efficacy, safety, and mode of action of treatment protocols, such as genetic recombination.
  • Homologous recombination (HR) between chromosomal and exogenous DNA is at the basis of methods for introducing genetic changes into the genome (Capecchi, Science 244: 1288-1292, 1989; Smithies et al., Nature 317: 230-234, 1985). Parameters of the recombination mechanism have been determined by studying plasmid sequences introduced into cells (Bernstein, et al., Mol. Cell Biol. 12: 360-367, 1992; Brenner et al., Proc. Natl. Acad. Sci. USA. 83: 1762-1766, 1986; Lin et al., Mol. Cell Biol. 10:113-119, 1990; Lin et al., Mol. Cell. Biol. 10: 103-112, 1990) and in in vitro system (Jessberger and Berg, Mol. Cell Biol. 11: 445-457, 1991). HR is promoted by double-strand breaks in DNA.
  • I-Sce I protein is an endonuclease responsible for intron horning in mitochondria of yeast, a non-reciprocal mechanism by which a predetermined sequence becomes inserted at a predetermined site.
  • endonuclease I-Sce I can catalyze recombination in the nucleus of yeast by initiating a double-strand break (Plessis et al., Genetics 130: 451-460, 1992).
  • the recognition site of endonuclease I-Sce I is 18 bp long, therefore, the I-Sce I protein is a very rare cutting restriction endonuclease in genomes (Gold et al., Nucleic Acids Res. 19: 189-90, 1991).
  • I-Sce I protein is not a recombinase, its potential for chromosome engineering is larger than that of systems with target site requirements on both host and donor molecules (Kilby et al., Reviews 9: 413-421, 1993).
  • the yeast I-Sce I endonuclease can efficiently induce double-strand breaks in a chromosomal target in mammalian cells and the breaks can be repaired using a donor molecule that shares homology with the regions flanking the break resulting in site-specific recombination, gene replacement, or insertion (U.S. Pat. No. 5,474,896).
  • the enzyme catalyzes recombination at a high efficiency. This demonstrates that recombination between chromosomal DNA and exogenous DNA can occur in mammalian cells by the double-strand break repair pathway (Szostak et al., Cell 33: 25-35, 1983).
  • I-SceI has been used for many different applications. Such applications have involved the study of double-stranded breaks, the investigation of chromosome structure, the study of transposition, inducing gene replacement in mammalian and bacterial cells, gene targeting by homologous recombination in Drosophila , and the production of chromosomal breaks in plants.
  • Anglana and Bacchetti Nucl. Acids Res. 27: 4276-4281, 1999; Bellaiche et al., Genetics 152: 1037-1044, 1999; Choulika et al., CR Acad. Sci. III 317: 1013-1019, 1994; Choulika et al., Mol. Cell Biol.
  • Group I introns are widespread in many evolutionary phylums because of their efficient propagation mechanism. Some of them encode homing endonucleases, which recognize the intron insertion site in an intronless cognate DNA-sequence and introduce double-strand breaks in the DNA near that site. Afterwards, the intron-containing gene acts as template for the repair of the cleaved recipient allele, in a gene conversion process, which leads to the duplication of the intervening sequence (1-4). In contrast to the group I intron homing, group II intron mobility is based on a retrohoming mechanism promoted by the intron encoded protein bound to the intron lariat, forming a ribonucleoprotein (RNP) particle.
  • RNP ribonucleoprotein
  • the RNP particle results in intron integration into the DNA target site by reversed splicing and reverse transcription of the intron RNA (5).
  • the protein component is endowed with endonucleolytic activity, which cuts the antisense strand.
  • the RNA After the RNA is positioned on the DNA it integrates into the sense strand before the antisense strand is cleaved by the protein part (6).
  • both intronic RNA and protein component of the RNP particle are involved in the recognition of the intron target site.
  • the latter element is also essential for DNA-unwinding (7). But not only group I- and group II-introns undergo homing.
  • LAGLIDADG homing endonucleases produce 4 bp 3′-OH overhangs near the intron insertion site (16-18). Conditions for optimal activity depend on the enzyme. For example, I-SceII prepared out of mitochondria (19) prefers temperatures around 30° C. and neutral pH whereas I-DmoI (18,20) prefers temperatures around 70° C. and alkaline pH-values. Unlike bacterial Type II restriction enzymes, homing endonucleases must have a very high recognition sequence specificity to exclude noxious effects on the host genome because no cognate modification system exists. Therefore, their recognition sites are much longer (14-30 bp, up to 40 bp for some intein encoded endonucleases).
  • intron encoded homing endonucleases rely on ⁇ -sheets to make their contacts with the DNA major groove. Hence their profile is very flat and they cover a wide area on the DNA (23,25), whereas the globular restriction endonucleases (26) usually interact via side chains from their ⁇ -helices with the target sequence (4).
  • LAGLIDADG consensus motifs
  • I-SceII Endonucleases with one motif bind their substrate as homodimers, whereas the enzymes with two LAGLIDADG motifs tend to act as monomers. Exceptions are I-SceII, encoded by intron aI4 ⁇ of the cox1 gene in S. cerevisiae , and I-SceIV from intron cox1I5 ⁇ of the same organism. I-SceII posseses two dodecapeptide motifs but is active as a homodimer (19). I-SceIV acts as a heterodimer (28).
  • Some proteins with two LAGLIDADG motifs are involved in splicing of their intron RNA. They are termed maturases (32,33). Maturases act as cofactors and stabilize the catalytic core of the intronic RNA structure for the splicing event (34,35). Some dodecapeptide endonucleases also bear a latent maturase activity, which can be revealed by mutation of a few amino acids (36-38). Only few of them reveal both activities simultaneously, as it was reported for I-AniI (39,40) and I-ScaI (41-43).
  • the reagents can be based on a restriction enzyme, especially with high specificity, its corresponding restriction site, and the gene encoding this enzyme.
  • this invention aids in fulfilling these needs in the art. Specifically, this invention relates to an isolated DNA encoding the enzyme I-SpomI.
  • a DNA sequence comprising a promoter operatively linked to the DNA sequence of the invention encoding the enzyme I-SpomI is provided.
  • This invention further relates to an isolated RNA complementary to the DNA sequence of the invention encoding the enzyme I-SpomI and to the other DNA sequences described herein.
  • a vector in another embodiment, is provided.
  • the vector can be a plasmid, bacteriophage, cosmid, or viral, particularly retroviral, vector containing the DNA sequence of the invention encoding the enzyme I-SpomI.
  • the vector can comprise a plasmid, bacteriophage, cosmid, or viral, particularly retroviral, vector containing the DNA sequence of the invention encoding an I-SpomI restriction site.
  • the invention also relates to a method for generating recombinant chromosomes and cells containing an I-SpomI restriction site.
  • the I-SpomI restriction site is introduced by recombination.
  • the invention further relates to a method for generating recombinant chromosomes and cells expressing I-SpomI enzyme.
  • a sequence coding for I-SpomI enzyme is introduced by recombination.
  • the invention also relates to a recombinant chromosome comprising an I-SpomI site or a DNA sequence encoding the enzyme I-SpomI.
  • the recombinant chromosome can be from a prokaryotic or eukaryotic organism.
  • the invention relates to a recombinant mammalian, yeast, fungal, bacterial, plant, nematode, or insect chromosome.
  • the invention relates to a recombinant drosophila, C. elegans , plant, or mouse chromosome.
  • this invention relates to prokaryotic, for example E. coli , or eukaryotic cells transformed with a vector of the invention.
  • the invention relates to a mammalian, yeast, fungal, bacterial, plant, nematode, or insect cell transformed with a vector of the invention.
  • the invention relates to a recombinant drosophila, C. elegans , plant, or mouse cell transformed with a vector of the invention.
  • the cells are stem cells, preferably mammalian stem cells and most preferably mouse stem cells. The invention further relates to cell lines derived from these cells.
  • this invention relates to transgenic organisms containing the DNA sequence encoding the enzyme I-SpomI and cell lines cultured from cells of the transgenic organisms.
  • this invention relates to a transgenic organism in which at least one restriction site for the enzyme I-SpomI has been inserted in a chromosome of the organism.
  • this invention relates to a method of genetically mapping a eukaryotic genome using the enzyme I-SpomI.
  • This invention also relates to a method for in vivo site directed recombination in an organism using the enzyme I-SpomI.
  • FIG. 1 depicts plasmid inserts.
  • FIG. 1A RNA secondary structure of cox1I1b intron of Schizosaccharomyces pombe .
  • the nucleotides encoding the core of the endonuclease consisting of the two LAGLIDADG motifs (P1 and P2) are located in loop 8 (L8).
  • L8 loop 8
  • a PCR-fragment including all codons of L8 was cloned into the expression vector pET16b. * represents the artificial start codon in primer SP003.
  • the box at the end of the loop marks the stop codon.
  • FIG. 1B Cloned fragments of the I-SpomI reading frame.
  • the top scheme symbolizes the entire sequence of the first exon (cox1E1) and the intron in the cox1 gene of S. pombe .
  • grey The exon cox1E1 with the native start codon ATG.
  • dark grey 912 nt of the 1560 nt of the entire ORF are located in the region that builds up L8 on the RNA level.
  • black coding sequence for the LAGLIDADG motifs.
  • light grey Sequences for the loops 1 to 7 are located in region a.
  • white The sequence non-coding region downstream to the TAA stop codon is located in loop L9.
  • Plasmid pSP005 lacks the entire 5′-exon part of the ORF, whereas pSP003 contained a fragment that is limited to the loop 8 part of the sequence.
  • the restriction enzymes, which were used for the cloning, are indicated.
  • FIG. 2 depicts expression and purification of I-SpomI.
  • FIG. 2A Purification chromatogram. His-tagged I-SpomI was expressed in E. coli as explained in the text. Subsequently to the E. coli cell-disruption, the supernatant was loaded onto a 1 ml HiTrap chelating affinity column (Amersham Pharmacia Biotech, Little Chalfont), charged with Ni 2+ and equilibrated with lysis buffer (30 mM HEPES pH8, 300 mM NaCl, 20 mM Imidazole) at a flow rate of 1 ml/min. The I-SpomI endonuclease is bound via its N-terminal His-tag while impurities are washed out with lysis buffer.
  • HiTrap chelating affinity column Amersham Pharmacia Biotech, Little Chalfont
  • Elution of the proteins was performed by increasing the imidazole concentration within the buffer, measured by conductivity.
  • FIG. 2B 12% SDS-PAGE of the peak fractions 4 to 11. Fraction 6 was used for the assays.
  • FIG. 2C Western blot of I-SpomI preparation after affinity chromatography. The band of the truncated protein appeared above the 36.5 kDa band of the unstained New England Biolabs Broad Range marker, which correlates well to the expected size of 38.7 kDa.
  • FIG. 3 depicts determination of the cleavage site of I-SpomI.
  • FIG. 3A Primers used for generating 5′ end-labeled I-SpomI-substrates. Both ends of each oligonucleotide are numbered according to the distance from the intron insertion site.
  • FIG. 3B Cleavage site of I-SpomI.
  • FIG. 4 depicts determination of optimal conditions for I-SpomI cleavage.
  • % cleaved product is expressed by the ratio between the signal from the 173 bp long cleaved fragment to the sum signal (signal of this fragment plus the radioactivity of the 273 bp uncleaved substrate).
  • FIG. 4A Mg 2+ -concentration. 1 ⁇ l of the PCR-product SP009-SP008 was incubated in a total volume of 25 ⁇ l with 5 ⁇ l of I-SpomI-solution.
  • the reaction buffer contained 0.1M Diethanolamine/HCl at pH9.0, 0.1M NaCl and MgCl 2 in various concentrations between 1 mM and 40 mM. The reactions were carried out for 20 min at 37° C.
  • FIG. 4B Na + -concentration.
  • the Reaction volume and the added volume of the PCR-product were as described under A.
  • the reaction buffer contained 0.1M Diethanolamine/HCl at pH9.0, MgCl 2 2.5 mM and NaCl in different concentrations between 0M and 0.2M. The reactions were incubated for 20 min at 37° C.
  • FIG. 4C Temperature.
  • the Reaction volume and the added volume of the PCR-product were as described under A.
  • the reaction buffer contained 0.1M Diethanolamine/HCl at pH9.0, MgCl 2 2.5 mM and NaCl 0.1M.
  • the reactions were incubated for 20 min at temperatures between 25° C. and 65° C.
  • FIG. 4D pH.
  • the Reaction volume and the added volume of the PCR-product were as described under A.
  • the reaction buffer contained 0.03M MES at pH 6.0, 0.1M HEPES at pH 7.0 or pH 8.0, 0.1M Diethanolamine/HCl at pH9.0, 9.2, 9.4, 9.6, 9.8 or pH 10, MgCl 2 2.5 mM and NaCl 0.1M.
  • the reactions were incubated for 20 min at 37° C.
  • FIG. 5 depicts determination of the I-SpomI recognition sequence.
  • FIG. 5A Electrophoretic analysis of NdeI-AlwNI fragments of plasmid pP3E5-2 after incubation with I-SpomI. DNA-fragments were revealed by Southern blotting and hybridization with random labeled pUC19. The 1 kb fragment contains the I-SpomI site, which generates two fragments of 0.8 kb and 0.2 kb respectively after cleavage by I-SpomI.
  • a set of plasmids was used, each plasmid containing a single nucleotide mutation of the wild type exon-exon sequence shown below. Each mutation corresponds to the transversion compared to the wild type sequence.
  • the staggered line indicates the cleavage site.
  • Percent values point out the relative cutting efficiency of I-SpomI on each mutated sequence relative to the wildtype sequence. Values represent the ratio in % between cleaved product and the mutated sequences for the wild type sequence.
  • the 0.8 kb band is compared to the total DNA present in the 1.0 kb and the 0.8 kb bands.
  • FIG. 5B Helical representation of the DNA-region. The arrows indicate the positions at which the strand breakage is introduced.
  • FIG. 6 depicts ORFs in peripheral loops of group I introns
  • the schematic diagram of the group I intron secondary structure shows the insertion sites of ORFs of LAGLIDADG type proteins.
  • FIG. 7 depicts the nucleotide sequence of the first exon of cox1 plus the intron coding for I-SpomI (SEQ ID NO:8).
  • FIG. 8 depicts a nucleotide sequence encoding the I-SpomI enzyme (SEQ ID NO:9).
  • FIG. 9 depicts the nucleotide sequence of an I-SpomI recognition site (SEQ ID NO:10).
  • FIG. 10 depicts the amino acid sequence of a natural I-SpomI protein (SEQ ID NO:11).
  • FIG. 11 depicts the amino acid sequence of an I-SpomI protein SEQ ID NO:12).
  • I-SpomI the gene product of the first group I intron in the mitochondrial cox1 gene of Schizosaccharomyces pombe , is endowed with endonuclease activity. It recognizes the flanking sequence around the intron insertion within the intronless cox1 allele. Major modifications in the N-terminus of I-SpomI compared to the gene product of the native reading frame did not affect cutting capability nor sequence specificity of the endonuclease. The position of the start codon of homing endonucleases is variable and can be located in various parts of the host gene.
  • the inventors have determined that the sequence of loop 8 intronic secondary structure of cox1I1b in S. pombe encodes a protein that acts as a specific endonuclease in vitro.
  • I-SpomI The optimum conditions for the in vitro activity of I-SpomI bear a striking resemblance to those preferred by I-SceI (29).
  • the preference for high pH values between 9.0 and 10.0 is rather unusual.
  • I-ScaI (43) shows best activity at pH8.0 to 9.0 and I-Crel (51) between pH7.0 and 9.0.
  • a characteristic feature shared with other LAGLIDADG endonucleases is the dependence on the divalent cation Mg 2+ , but the influence of other cofactors like Mn 2+ or Zn 2+ on cutting activity was not checked.
  • I-SpomI shows the typical 3′-overhang of 4nt length as it has been described for many other endonucleases of the LAGLIDADG type of different kingdoms, for example I-AniI (39), I-ScaI (43), I-SceI (16), II (37) and III (56) I-CeuI (30), I-ChuI (57), I-CreI (17), I-CpaII (58), I-DmoI (20), I-PorI (59), PI-SceI (60), PI-ThyI (61), PI-TliI (62) and PI-TfuII (63) and also the HO endonuclease of S.
  • I-SpomI cleaves the sense strand and the antisense strand 2 nt away from the intron insertion site.
  • the recognition site of I-SpomI is 20 nt in length.
  • I-SpomI Like other intron encoded homing endonucleases, I-SpomI recognizes a long DNA sequence although the protein is rather small in comparison to bacterial restriction endonucleases. Bacterial type II restriction enzymes engulf the DNA and nearly saturate the hydrogen bond donors in the major groove and in addition they often contact the minor groove of the recognition site (26). Since the profile of intron encoded homing endonucleases, based on ⁇ -sheets, is flat, they interact with the specific bases of the recognition site over the DNA major groove without using additional chains so that they make subsaturating contacts (4).
  • the inventors hypothesize a contact to the substrate DNA from one side in which the catalytic domain of the enzyme faces the minor DNA groove while the two recognition domains face the neighboring major grooves. This also explains the independence of recognition on the four central bases, flanked by essential bases. Although the order of essential and non-essential nucleotides within the I-SpomI recognition site is symmetric, there is no palindromic sequence present like for homodimeric LAGLIDADG enzymes like I-CreI (66). In general, endonuclease domains of monomeric dodecapeptide endonucleases bear a pronounced asymmetry in comparison to the homodimeric enzymes. This causes relaxed symmetry requirement for the recognition site and allows the acquisition of an expanded range of substrates (3,67). Recognition and cutting sequences of the dodecapeptide homing endonucleases are highly divergent.
  • I-AniI (39) is the closest relative to I-SpomI, but neither cutting nor recognition sites resemble those of I-SpomI.
  • Homing endonuclease ORFs occur in different peripherical loops of the RNA secondary structure of group I introns after invasion of these exposed loops (2,68-70).
  • the intron and the intronic ORF are regarded as independent genetic elements (71).
  • I-TevII an alignment of exon junction sequences of the phage T4 sunY gene and intron sequences flanking the ORF in loop L9.1 revealed a high degree of similarity spanning the I-TevII, recognition sequence (72).
  • I-ScaI The recently purified I-ScaI was the first reported protein to have both endonuclease and maturase activity, whereas the maturase homologue in intron bi2 of the cyt b gene in S. cerevisiae is dependent on a replacement of two non-adjacent amino acids to gain the endonuclease activity (38,41,42).
  • Another protein containing both activities is I-AniI, encoded by a mitochondrial group I intron in Emericella nidulans (39). Proteins that contain both activities might represent intermediates in this evolution.
  • This invention relates to an isolated DNA sequence encoding the enzyme I-SpomI.
  • the enzyme I-SpomI is an endonuclease, especially a DNA endonuclease.
  • the first group I intron of the cox1 gene (cox1I1b) of the mitochondrial genome of the fission yeast Schizosaccharomyces pombe contains an open reading frame encoding a polypeptide, which is a typical member of the LAGLIDADG protein family with two consensus motifs.
  • Biochemical characterization of the endonuclease activity of this protein artificially expressed in E. coli has been performed and a translation product of 304 codons of the cox1I1b ORF located in loop 8 of the intron RNA secondary structure exhibits a specific endonuclease activity in vitro.
  • the optimal in vitro conditions for endonucleolytic cleavage were characterized, and using such conditions the cleavage and recognition site of the protein were determined. Consistent with the findings from other LAGLIDADG proteins, I-SpomI generates a doubl-strand break with 4 nt 3′-overhangs near the intron insertion site and recognizes a novel sequence of 20 nucleotides.
  • the DNA sequence encoding the enzyme I-SpomI be in a purified form.
  • the DNA sequence of the invention is free of extraneous proteins and lipids, and adventitious microorganisms, such as bacteria and viruses.
  • the essentially purified and isolated DNA sequence encoding I-SpomI is especially useful for preparing expression vectors.
  • the gene of the invention can be prepared by the formation of 3′- ->5′ phosphate linkages between nucleoside units using conventional chemical synthesis techniques.
  • conventional chemical synthesis techniques for example, the well-known phosphodiester, phosphotriester, and phosphite triester techniques, as well as known modifications of these approaches, can be employed.
  • Deoxyribonucleotides can be prepared with automatic synthesis machines, such as those based on the phosphoramidite approach. Oligo- and polyribonucleotides can also be obtained with the aid of RNA polymerase and ligase using conventional techniques.
  • This invention of course includes variants of the DNA sequence of the invention exhibiting substantially the same properties as the sequence of the invention.
  • DNA sequences need not be identical to the sequence disclosed herein.
  • a DNA sequence can vary from that shown in FIG. 7 and still encode a protein having the same amino acid sequence as that encoded by FIG. 7 .
  • Variations can be attributable to single or multiple base substitutions, deletions, or insertions or local mutations involving one or more nucleotides not substantially detracting from the properties of the DNA sequence as encoding an enzyme having the cleavage properties of the enzyme I-SpomI.
  • I-SpomI enzyme is meant to include variants and fragments of the native protein retaining the ability to cleave the I-SpomI restriction site.
  • the invention provides isolated and purified or homogeneous, I-SpomI polypeptides, both recombinant and non-recombinant.
  • Variants and derivatives of native I-SpomI proteins that retain the desired biological activity can be obtained by mutations of nucleotide sequences coding for native I-SpomI polypeptides. Alterations of the native amino acid sequence can be accomplished by any of a number of conventional methods. Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.
  • oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene, wherein predetermined codons can be altered by substitution, deletion, or insertion.
  • Exemplary methods of making the alterations set forth above are disclosed by Walder et al. ( Gene 42:133, 1986); Bauer et al. ( Gene 37:73, 1985); Craik ( BioTechniques , January 1985, 12-19); Smith et al. ( Genetic Engineering: Principles and Methods , Plenum Press, 1981); Kunkel ( Proc. Natl. Acad. Sci. USA 82:488, 1985); Kunkel et al. ( Methods in Enzymol. 154:367, 1987); Sambrook et al. ( Molecular Cloning: A Laboratory Manual, 3 ed., Cold Spring Harbor Laboratory Press, 2001), and U.S. Pat. Nos. 4,518,584 and 4,737,462, all of which are incorporated by reference.
  • the DNA sequence of the invention coding for the enzyme I-SpomI can be amplified in the well known polymerase chain reaction (PCR), which is useful for amplifying all or specific regions of the gene. See e.g. S. Kwok et al., J. Virol., 61:1690-1694 (1987); U.S. Pat. No. 4,683,202; and U.S. Pat. No. 4,683,195. More particularly, DNA primer pairs of known sequence positioned 10-300 base pairs apart that are complementary to the plus and minus stands of the DNA to be amplified can be prepared by well known techniques for the synthesis of oligonucleotides.
  • PCR polymerase chain reaction
  • each primer can be extended and modified to create restriction endonuclease sites when the primer is annealed to the DNA.
  • the PCR reaction mixture can contain the DNA, the DNA primer pairs, four deoxyribonucleoside triphosphates, MgCl 2 , DNA polymerase, and conventional buffers.
  • the DNA can be amplified for a number of cycles. It is generally possible to increase the sensitivity of detection by using a multiplicity of cycles, each cycle consisting of a short period of denaturation of the DNA at an elevated temperature, cooling of the reaction mixture, and polymerization with the DNA polymerase. Amplified sequences can be detected by the use of techniques known by those skilled in the art.
  • the DNA sequence of the invention coding for the enzyme I-SpomI can also be used as a probe for the detection of a nucleotide sequence in a biological material.
  • the probe can be labeled with an atom or inorganic radical, most commonly using a radionuclide, or with any non-radioactive material commonly used in molecular biology experiments.
  • Radioactive labels include 32 P, 3 H, 14 C, or the like. Any radioactive label can be employed, which provides for an adequate signal and has sufficient half-life.
  • Other labels include ligands that can serve as a specific binding member to a labeled antibody, fluorescers, chemiluminescers, enzymes, antibodies which can serve as a specific binding pair member for a labeled ligand, and the like. The choice of the label will be governed by the effect of the label on the rate of hybridization and binding of the probe to the DNA or RNA. It will be necessary that the label provide sufficient sensitivity to detect the amount of DNA or RNA available for hybridization
  • the nucleotide sequence of the invention When the nucleotide sequence of the invention is used as a probe for hybridizing to a gene, the nucleotide sequence tested with the probe is preferably affixed to a water insoluble solid, porous support, such as nylon membrane.
  • Hybridization can be carried out using labeled polynucleotides of the invention and conventional hybridization reagents. The particular hybridization technique is not essential to the invention.
  • the amount of labeled probe present in the hybridization solution will vary widely, depending upon the nature of the label, the amount of the labeled probe which can reasonably bind to the support, and the stringency of the hybridization. Generally, substantial excesses of the probe over stoichiometric will be employed to enhance the rate of binding of the probe to the fixed DNA or RNA.
  • Various degrees of stringency of hybridization can be employed. The more severe the conditions, the greater the complementarity that is required for hybridization between the probe and the polynucleotide for duplex formation. Severity can be controlled by temperature, probe concentration, probe length, ionic strength, time, and the like. Conveniently, the stringency of hybridization is varied by changing the polarity of the reactant solution. Temperatures to be employed can be empirically determined or determined from well known formulas developed for this purpose.
  • Preferred hybridization conditions include standard hybridization conditions, such as those described in Church and Gilbert, Proc Natl Acad Sci U S A, 1984, April; 81(7):1991-5, and Church and Gilbert, Prog Clin Biol Res, 1985, 177(2):17-21, both which are specifically incorporated by reference.
  • This invention also relates to the DNA sequence of the invention encoding the enzyme I-SpomI or an I-SpomI restriction site, wherein the nucleotide sequence is linked to other nucleic acids.
  • the nucleic acid can be obtained from any source, for example, from plasmids, from cloned DNA or RNA, or from natural DNA or RNA from any source, including prokaryotic and eukaryotic organisms.
  • the nucleic acid can be a recombinant chromosome into which a nucleic acid encoding I-SpomI enzyme has been introduced.
  • the nucleic acid can be a recombinant chromosome into which an I-SpomI restriction site has been introduced.
  • DNA or RNA can be extracted from a biological material, such as microbial cultures, biological fluids or tissue, by a variety of techniques including those described by Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, New York (2001).
  • the nucleic acid will generally be obtained from a bacteria, yeast, virus, or a higher organism, such as a plant or animal.
  • the nucleic acid can be a fraction of a more complex mixture, such as a portion of a gene contained in whole human DNA or a portion of a nucleic acid sequence of a particular microorganism.
  • the nucleic acid can be a fraction of a larger molecule or the nucleic acid can constitute an entire gene or assembly of genes.
  • the DNA can be in a single-stranded or double-stranded form. If the fragment is in single-sanded form, it can be converted to double-stranded form using DNA polymerase according to conventional techniques.
  • the DNA sequence of the invention can be linked to a structural gene.
  • structural gene refers to a DNA sequence that encodes through its template or messenger mRNA a sequence of amino acids characteristic of a specific protein or polypeptide.
  • the nucleotide sequence of the invention can function with an expression control sequence, that is, a DNA sequence that controls and regulates expression of the gene when operatively linked to the gene.
  • This invention also relates to cloning and expression vectors containing the DNA sequence of the invention coding for the enzyme I-SpomI or an I-SpomI restriction site.
  • the DNA sequence encoding the enzyme can be ligated to a vehicle for cloning the sequence.
  • the major steps involved in gene cloning comprise procedures for separating DNA containing the gene of interest from prokaryotes or eukaryotes, cutting the resulting DNA fragment and the DNA from a cloning vehicle at specific sites, mixing the two DNA fragments together, and ligating the fragments to yield a recombinant DNA molecule.
  • the recombinant molecule can then be transferred into a host cell, and the cells allowed to replicate to produce identical cells containing clones of the original DNA sequence.
  • the vehicle employed in this invention can be any single- or double-stranded DNA molecule capable of transporting the nucleotide sequence of the invention into a host cell.
  • the vehicle When the vehicle is also capable of replicating within the cell, it must contain at least one DNA sequence that can act as the origin of replication in the host cell.
  • the vehicle must contain one or more sites for insertion of the DNA sequence encoding the gene of the invention. These sites will ordinarily correspond to restriction enzyme sites at which cohesive ends can be formed, and which are complementary to the cohesive ends on the promoter sequence to be ligated to the vehicle.
  • this invention can be carried out with plasmid, bacteriophage, cosmid vehicles, bacterial artificial chromosomes (BAC), or yeast artificial chromosomes (YAC) having these characteristics.
  • the nucleotide sequence of the invention can have cohesive ends compatible with any combination of sites in the vehicle.
  • the sequence can have one or more blunt ends that can be ligated to corresponding blunt ends in the cloning sites of the vehicle.
  • the nucleotide sequence to be ligated can be further processed, if desired, by successive exonuclease deletion, such as with the enzyme Bal 31 or ⁇ exo III.
  • the sequence can be modified by adding a linker, an adaptor, or homopolymer tailing.
  • vehicles for example plasmids, used for cloning nucleotide sequences of the invention carry one or more genes responsible for a useful characteristic, such as a selectable marker, displayed by the host cell.
  • vehicles having genes for resistance to two different drugs are chosen. For example, insertion of the DNA sequence into a gene for an antibiotic inactivates the gene and destroys drug resistance. The second drug resistance gene is not affected when cells are transformed with the recombinants, and colonies containing the gene of interest can be selected by resistance to the second drug and susceptibility to the first drug.
  • Preferred antibiotic markers are genes imparting chloramphenicol, ampicillin, or tetracycline resistance to the host cell.
  • restriction enzymes can be used to cut the vehicle.
  • the identity of the restriction enzyme will generally depend upon the identity of the ends on the DNA sequence to be ligated and the restriction sites in the vehicle.
  • the restriction enzyme is matched to the restriction sites in the vehicle, which in turn is matched to the ends on the nucleic acid fragment being ligated.
  • the ligation reaction can be set up using well known techniques and conventional reagents. Ligation is carried out with a DNA ligase that catalyzes the formation of phosphodiester bonds between adjacent 5′-phosphate and the free 3′-hydroxy groups in DNA duplexes.
  • the DNA ligase can be derived from a variety of microorganisms.
  • the preferred DNA ligases are enzymes from E. coli and bacteriophage T4.
  • T4 DNA ligase can ligate DNA fragments with blunt or sticky ends, such as those generated by restriction enzyme digestion.
  • E. coli DNA ligase can be used to catalyze the formation of phosphodiester bonds between the termini of duplex DNA molecules containing cohesive ends.
  • Cloning can be carried out in prokaryotic or eukaryotic cells.
  • the host for replicating the cloning vehicle will of course be one that is compatible with the vehicle and in which the vehicle can replicate.
  • the plasmid can be derived from bacteria or some other organism or the plasmid can be synthetically prepared.
  • the plasmid can replicate independently of the host cell chromosome or an integrative plasmid can be employed.
  • the plasmid can make use of the DNA replicative enzymes of the host cell in order to replicate or the plasmid can carry genes that code for the enzymes required for plasmid replication.
  • a number of different plasmids can be employed in practicing this invention.
  • the DNA sequence of the invention encoding the enzyme I-SpomI can also be ligated to a vehicle to form an expression vector.
  • the vehicle employed in this case is one in which it is possible to express the gene operatively linked to a promoter in an appropriate host cell. It is preferable to employ a vehicle known for use in expressing genes in bacteria, for example E. coli , yeast, insect, fungi, nematode, plant, or mammalian cells.
  • the present invention also provides recombinant cloning and expression vectors containing DNA, as well as host cell containing the recombinant vectors.
  • Guidance can be found in laboratory guides such as Current Protocols in Molecular Biology (Ausubel et al., Wiley, 1998).
  • Expression vectors comprising DNA may be used to prepare the I-SpomI enzyme.
  • a method for producing I-SpomI enzyme comprises culturing host cells transformed with a recombinant expression vector encoding the I-SpomI enzyme, under conditions that promote expression of the enzyme, then recovering the expressed enzyme, from the culture.
  • the skilled artisan will recognize that the procedure for purifying the expressed enzyme will vary according to such factors as the type of host cells employed, and whether the polypeptide is membrane-bound or a soluble form that is secreted from the host cell.
  • the vectors include a DNA encoding a polypeptide or fragment of the invention, operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene.
  • suitable transcriptional or translational regulatory nucleotide sequences such as those derived from a mammalian, microbial, viral, or insect gene.
  • regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination.
  • Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA sequence.
  • a promoter nucleotide sequence is operably linked to a DNA sequence if the promoter nucleotide sequence controls the transcription of the DNA sequence.
  • An origin of replication that confers the ability to replicate in the desired host cells, and a selection gene by which transformants are identified, are generally incorporated into the expression vector.
  • a sequence encoding a peptide for example an appropriate signal peptide (native or heterologous), can be incorporated into expression vectors.
  • a DNA sequence for a signal peptide secretory leader may be fused in frame to the nucleic acid sequence of the invention so that the DNA is initially transcribed, and the mRNA translated, into a fusion protein comprising the signal peptide.
  • a signal peptide that is functional in the intended host cells promotes extracellular secretion of the polypeptide. The signal peptide is cleaved from the polypeptide upon secretion of polypeptide from the cell.
  • a protein preparation may include a mixture of protein molecules having different N-terminal amino acids, resulting from cleavage of the signal peptide at more than one site.
  • Suitable host cells for expression of polypeptides include prokaryotes, yeast or higher eukaryotic cells. Mammalian, nematode, plant, bacterial, fungal, yeast, or insect cells are generally preferred for use as host cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. Cloning Vectors: A Laboratory Manual , Elsevier, N.Y. (1985). Cell-free translation systems could also be employed to produce polypeptides using RNAs derived from DNA constructs disclosed herein.
  • Prokaryotes include gram-negative or gram-positive organisms. Suitable prokaryotic host cells for transformation include, for example, E. coli, Bacillus subtilis, Salmonella typhimurium , and various other species within the genera Pseudomonas, Streptomyces , and Staphylococcus .
  • a polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant polypeptide.
  • Expression vectors for use in prokaryotic host cells generally comprise one or more phenotypic selectable marker genes.
  • a phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement.
  • useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017) or vectors derived from pBR322, such as vectors from the puC group.
  • pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.
  • An appropriate promoter and a DNA sequence are inserted into the pBR322 vector.
  • Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, Wis., USA).
  • Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include ⁇ -lactamase (penicillinase), lactose promoter system (Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980; and EP-A-36776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, p. 412, 1982).
  • ⁇ -lactamase penicillinase
  • lactose promoter system Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979
  • tryptophan (trp) promoter system Goeddel et al., Nucl. Acids Res. 8:
  • a particularly useful prokaryotic host cell expression system employs a phage ⁇ P L promoter and a cI857ts thermolabile repressor sequence.
  • Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the ⁇ P L promoter include plasmid pHUB2 (resident in E. coli strain JMB9, ATCC 37092) and pPLc28 (resident in E. coli RR1, ATCC 53082).
  • the polypeptides may be expressed in yeast host cells, preferably from the Saccharomyces genus (e.g., S. cerevisiae ). Other genera of yeast, such as Pichia or Kluyveromyces , may also be employed.
  • yeast vectors will often contain an origin of replication sequence from a 2 ⁇ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene.
  • Suitable promoter sequences for yeast vectors include, among others, galactose-regulated promoters such as GRAP1 sequence ( Molecular Generics of Yeast , John R.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase.
  • suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657.
  • Another alternative is the glucose-repressible ADH2 promoter described by Russell et al. ( J. Biol. Chem.
  • the vectors are preferably shuttle vectors.
  • Shuttle vectors replicable in both yeast and E. coli may be constructed by inserting DNA sequences from pBR322 for selection and replication in E. coli (Amp r gene and origin of replication) into the above-described yeast vectors.
  • the yeast ⁇ -factor leader sequence may be employed to direct secretion of the polypeptide.
  • the ⁇ -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kujan et al., Cell 30:933, 1982 and Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, 1984.
  • Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art.
  • a leader sequence may be modified near its 3′ end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.
  • Yeast transformation protocols are known to those of skill in the art.
  • One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929, 1978.
  • the Hinnen et al. protocol selects for Leu + transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 2% glucose, 10 mg/ml adenine and 20 mg/ml uracil.
  • Yeast host cells transformed by vectors containing an ADH2 promoter sequence may be grown for inducing expression in a “rich” medium.
  • a rich medium is one consisting of 1% yeast extract, 1% peptone, and 2% glucose. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.
  • Mammalian or insect host cell culture systems also may be employed to express recombinant polypeptides.
  • Bacculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988).
  • Established cell lines of mammalian origin also may be employed.
  • suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., Cell 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV1/EBNA cell line derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al. ( EMBO J. 10: 2821, 1991).
  • DHFR dihydrofolate reductase
  • a suitable host stain for DIFR selection can be CHO strain DX-B11, which is deficient in DFR (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980).
  • a plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only cells that contain the plasmid can grow in the appropriate selective media
  • selectable markers include cDNAs conferring resistance to antibiotics, such as G418 and hygromycin B. Cells harboring the vector can be selected on the basis of resistance to these compounds.
  • Transcriptional and translational control sequences for mammalian host cell expression vectors can be excised from viral genomes.
  • Commonly used promoter sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus.
  • DNA sequences derived from the SV40 viral genome for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell.
  • Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., Nature 273:113, 1978; Kaufman, Meth. in Enzymology, 1990). Smaller or larger SV40 fragments can also be used, provided the approximately 250 bp sequence extending from the Hind III site toward the Bgl I site located in the SV40 viral origin of replication site is included.
  • Additional control sequences shown to improve expression of heterologous genes from mammalian expression vectors include such elements as the expression augmenting sequence element (EASE) derived from CHO cells (Morris et al., Animal Cell Technology, 1997, pp. 529-534 and PCT Application WO 97/25420) and the tripartite leader (TPL) and VA gene RNAs from Adenovirus 2 (Gingeras et al., J. Biol. Chem. 257:13475-13491, 1982).
  • EASE expression augmenting sequence element
  • TPL tripartite leader
  • VA gene RNAs from Adenovirus 2
  • the internal ribosome entry site (IRES) sequences of viral origin allows dicistronic mRNAs to be translated efficiently (Oh and Sarnow, Current Opinion in Genetics and Development 3:295-300, 1993; Ramesh et al., Nucleic Acids Research 24:2697-2700, 1996).
  • IRS internal ribosome entry site
  • a heterologous cDNA as part of a dicistronic mRNA followed by the gene for a selectable marker (e.g. DHFR) has been shown to improve transfectability of the host and expression of the heterologous cDNA (Kaufman, Meth. in Enzymology, 1990).
  • Exemplary expression vectors that employ dicistronic mRNAs are pTR-DC/GFP described by Mosser et al., Biotechniques 22:150-161, 1997, and p2A5I described by Morris et al., Animal Cell Technology, 1997, pp. 529-534.
  • a useful high expression vector, pCAVNOT has been described by Mosley et al., Cell 59:335-348, 1989.
  • Other expression vectors for use in mammalian host cells can be constructed as disclosed by Okayama and Berg ( Mol. Cell. Biol. 3:280, 1983) and Sambrook et al. ( Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, New York, 2001), for example.
  • a useful system for stable high level expression of mammalian cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. ( Mol. Immunol. 23:935, 1986). Additional useful mammalian expression vectors are described in EP-A-0367566, and in WO 91/18982, incorporated by reference herein.
  • FLAG® is centered on the fusion of a low molecular weight (1 kD), hydrophilic, FLAG® marker peptide to the N-terminus of a recombinant protein expressed by pFLAG® expression vectors.
  • pDC311 is another specialized vector used for expressing proteins in CHO cells.
  • pDC311 is characterized by a bicistronic sequence containing the gene of interest and a dihydrofolate reductase (DBFR) gene with an internal ribosome binding site for DHFR translation, an expression augmenting sequence element (EASE), the human CMV promoter, a tripartite leader sequence, and a polyadenylation site.
  • DBFR dihydrofolate reductase
  • the native signal peptide may be replaced by a heterologous signal peptide or leader sequence, if desired.
  • the choice of signal peptide or leader may depend on factors such as the type of host cells in which the recombinant polypeptide is to be produced.
  • heterologous signal peptides that are functional in mammalian host cells include the signal sequence for interleukin-7 (IL-7) described in U.S. Pat.
  • I-SpomI may be either constitutive or inducible. If inducibility is desired, an inducible promoter may be used. Examples of inducible systems are given in Brown, U.S. Pat. No.6,180,391; Yee et al., U.S. Pat. No. 6,133,027; Reeves, U.S. Pat. No. 5,965,440; and Filmus et al., U.S. Pat. No. 5,877,018.
  • the invention also includes methods of isolating and purifying the polypeptides and fragments thereof.
  • the purification of recombinant polypeptides or fragments can be accomplished using fusions of polypeptides or fragments of the invention to another polypeptide to aid in the purification of polypeptides or fragments of the invention.
  • fusion partners can include the poly-His, HA-GST, or other antigenic identification peptides, as well as Fc moieties.
  • the purification is accomplished by the Tap-Tag technique (Rigaut et al., Nat. Biotechnol. 1999 October; 17(10):1030-2).
  • the recombinant polypeptide or fragment can be isolated from the host cells if not secreted, or from the medium or supernatant if soluble and secreted, followed by one or more concentration, salting-out, ion exchange, hydrophobic interaction, affinity purification or size exclusion chromatography steps.
  • the culture medium first can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • the concentrate can be applied to a purification matrix such as a gel filtration medium.
  • an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups.
  • the matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
  • a cation exchange step can be employed.
  • Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.
  • a chromatofocusing step can be employed.
  • a hydrophobic interaction chromatography step can be employed.
  • Suitable matrices can be phenyl or octyl moieties bound to resins.
  • affinity chromatography with a matrix which selectively binds the recombinant protein can be employed. Examples of such resins employed are lectin columns, dye columns, and metal-chelating columns.
  • one or more reversed-phase high performance liquid chromatography (RFP-PLC) steps employing hydrophobic RP-HPLC media, (e.g., silica gel or polymer resin having pendant methyl, octyl, octyldecyl or other aliphatic groups) can be employed to farther purify the polypeptides.
  • RFP-PLC reversed-phase high performance liquid chromatography
  • hydrophobic RP-HPLC media e.g., silica gel or polymer resin having pendant methyl, octyl, octyldecyl or other aliphatic groups
  • an affinity column comprising a polypeptide-binding protein of the invention, such as a monoclonal antibody generated against polypeptides of the invention, to affinity-purify expressed polypeptides.
  • polypeptides can be removed from an affinity column using conventional techniques, e.g., in a high salt elution buffer and then dialyzed into a lower salt buffer for use or by changing pH or other components depending on the affinity matrix utilized, or be competitively removed using the naturally occurring substrate of the affinity moiety, such as a polypeptide derived from the invention.
  • polypeptide-binding proteins such as anti-polypeptide antibodies or other proteins that interact with the polypeptide of the invention
  • a solid phase support such as a column chromatography matrix or a similar substrate suitable for identifying, separating, or purifying cells that express polypeptides of the invention on their surface.
  • Adherence of polypeptide-binding proteins of the invention to a solid phase contacting surface can be accomplished by any means, for example, magnetic microspheres can be coated with these polypeptide-binding proteins and held in the incubation vessel through a magnetic field. Suspensions of cell mixtures are contacted with the solid phase that has such polypeptide-binding proteins thereon.
  • Cells having polypeptides of the invention on their surface bind to the fixed polypeptide-binding protein and unbound cells then are washed away.
  • This affinity-binding method is useful for purifying, screening, or separating such polypeptide-expressing cells from solution.
  • Methods of releasing positively selected cells from the solid phase are known in the art and encompass, for example, the use of enzymes. Such enzymes are preferably non-toxic and non-injurious to the cells and are preferably directed to cleaving the cell-surface binding partner.
  • mixtures of cells suspected of containing polypeptide-expressing cells of the invention first can be incubated with a biotinylated polypeptide-binding protein of the invention. Incubation periods are typically at least one hour in duration to ensure sufficient binding to polypeptides of the invention.
  • the resulting mixture then is passed through a column packed with avidin-coated beads, whereby the high affinity of biotin for avidin provides the binding of the polypeptide-binding cells to the beads.
  • avidin-coated beads is known in the art. See Berenson, et al. J. Cell. Biochem., 10D:239 (1986). Wash of unbound material and the release of the bound cells is performed using conventional methods.
  • the desired degree of purity depends on the intended use of the protein.
  • a relatively high degree of purity is desired when the polypeptide is to be administered in vivo, for example.
  • the polypeptides are purified such that no protein bands corresponding to other proteins are detectable upon analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). It will be recognized by one skilled in the pertinent field that multiple bands corresponding to the polypeptide may be visualized by SDS-PAGE, due to differential glycosylation differential post-translational processing, and the like.
  • the polypeptide of the invention is purified to substantial homogeneity, as indicated by a single protein band upon analysis by SDS-PAGE. The protein band may be visualized by silver staining, Coomassie blue staining, or (if the protein is radiolabeled) by autoradiography.
  • the nucleic acids of the invention can be introduced into host cells using conventional techniques.
  • the nucleic acids can be introduced by calcium phosphate precipitation (Graham & Van Der Eb, Virology, 52:456-467, 1973; Chen & Okayama, Mol. Cell Biol., 7:2745-2752, 1987; Rippe et al., Mol. Cell Biol., 10:689-695, 1990) DEAE-dextran (Gopal., Mol. Cell Biol., 5:1188-1190, 1985), electroporation (Tur-Kaspa et al., Mol. Cell Biol., 6:716-718, 1986), direct microinjection (Harland & Weintraub, J.
  • Preferred cells are bacterial, plant, nematode, yeast, insect, and mammalian. Pure microbial cultures can be used. Particularly preferred are drosophila and mouse cells. Cells can be primary cells or a cell line. Cells can contain the nucleic acid integrated into the genome. Alternatively, the nucleic acid may remain unintegrated. In a preferred embodiment, a recombinant mammalian or insect chromosome contains an integrated I-SpomI site. Particularly preferred is a drosophila, C. elegans , or murine chromosome.
  • a recombinant bacterial, plant, nematode, yeast, mammalian, or insect chromosome contains an nucleic acid that expresses I-SpomI enzyme.
  • a drosophila, C. elegans , or murine chromosome is particularly preferred.
  • Cloning can be carried out in prolaryotic or eukaryotic cells.
  • the host for replicating the cloning vehicle will of course be one that is compatible with the vehicle and in which the vehicle can replicate.
  • Cloning is preferably carried out in bacterial or yeast cells, although cells of fungal, animal, and plant origin can also be employed.
  • the preferred host cells for conducting cloning work are bacterial cells, such as E. coli .
  • E. coli cells is particularly preferred because most cloning vehicles, such as bacterial plasmids and bacteriophages, replicate in these cells.
  • an expression vector containing the DNA sequence encoding the nucleotide sequence of the invention operatively linked to a promoter is inserted into a mammalian cell using conventional techniques.
  • Adenovirus has been used to efficiently deliver I-SceI to human cells (Anglana and Bacchetti, Nucleic Acids Research 27: 4276-4281, 1999). Adenovirus has also been used as a vector to deliver HO endonuclease (Nicolas et al., Virology 266: 211-244, 2000). Adenovirus vectors can be use to deliver nucleic acid encoding I-SpomI enzyme.
  • adenovirus a 36 kB, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB (Grunhaus & Horwitz, Adenovirus as cloning vector, Seminar in Virology 3: 237-252, 1992).
  • the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity.
  • adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage.
  • Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity.
  • Generation and propagation of adenovirus vectors, which are replication deficient, depend on a helper cell line, which constitutively expresses adenovirus proteins (e.g., Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5 ,” J. Gen. Virol. 36: 59-79, 1977).
  • Adenovirus vectors have been used in eukaryotic gene expression (Levrero et al., “Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo,” Gene 101: 195-202, 1991; Gomez-Foix et al., “Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen,” J. Biol. Chem.
  • Retroviral vectors can be used to deliver nucleic acid encoding I-SpomI enzyme or an I-SpomI site to cells.
  • the use of a retroviral vector facilitates integration of the nucleic acid into a host chromosome.
  • the retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, “Retroviridae and their replication,” In: Virology; Fields et al. (eds.), New York: Raven Press, pp. 1437-1500, 1990).
  • the resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins.
  • the integration results in the retention of the viral gene sequences in the recipient cell and its descendants.
  • a nucleic acid encoding a gene of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective.
  • a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann et al., “Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus,” Cell 33:153-159, 1983).
  • Retroviral vectors In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez & Denhardt (eds.), Stoneham: Butterworth, pp. 493-513, 1988; Temin, In: Gene Transfer, Kucherlapati (ed.), New York: Plenum Press, pp. 149-188, 1986; Mann et al., Cell, 33:153-159, 1983).
  • the media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types.
  • viral vectors may be employed as expression or delivery constructs in the present invention.
  • Vectors derived from viruses such as vaccinia virus (Ridgeway, “Mammalian expression vectors,” In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez & Denhardt (eds.), Stoneham: Butterworth, pp. 467-92, 1988; Baichwal & Sugden, “Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes,” In: Gene transfer, Kucherlapati (ed.), New York: Plenum Press, pp.
  • stem cells containing nucleic acid encoding I-SpomI enzyme or an I-SpomI site can be prepared.
  • the routine insertion of specific genes into the mouse genome can be accomplished through the use of mouse ES cells (see e.g., Kusakabe et al., U.S. Pat. No. 6,190,910).
  • Mouse ES cells are undifferentiated, pluripotent cells derived in vitro from preimplantation embryos (Evans, et al. Nature 292: 154-159, 1981; Martin, Proc. Natl. Acad. Sci. USA 78: 7634-7638, 1981) or from fetal germ cells (Matsui, et al., Cell 70: 841-847, 1992).
  • Mouse ES cells maintain an undifferentiated state through serial passages (Williams, et al. Nature 336: 684-687, 1988).
  • the ability of mouse ES cells to contribute to functional germ cells in chimeras provides a method for introducing site-specific mutations into mouse lines.
  • homologous recombination can be used to derive ES cell lines with planned alterations of specific genes (see, e.g., Jaisser et al., U.S. Pat. No.5,830,729). These genetically altered cells can be used to form chimeras with normal embryos and chimeric animals are recovered.
  • ES cells contribute to the germ line in the chimeric animal, then in the next generation a mouse line for the planned mutation is established.
  • the mouse D3 embryonic stem cell line is used.
  • Other ES cells such as bovine stem cells (Sims et al. U.S. Pat. No. 6,107,543), can similarly be used.
  • transgenic animals conventional techniques can be used.
  • ES cells can be used to generate transgenic animals.
  • plasmids encoding I-SpomI enzyme or an I-SpomI restriction site can be injected into the male pronuclei of fertilized one-cell mouse eggs. The injected eggs can then transferred to pseudo-pregnant foster females. The eggs in the foster females are allowed to develop to term.
  • the nested chromosomal fragmentation strategy for genetically mapping a eukaryotic genome exploits the unique properties of the restriction endonuclease I-SpomI, such as a 20 bp long recognition site; The absence of natural I-SpomI recognition sites in most eukaryotic genomes is also exploited in this mapping strategy.
  • one or more I-SpomI recognition sites are artificially inserted at various positions in a genome, by homologous recombination using specific cassettes containing selectable markers or by random insertion, as discussed supra.
  • the genome of the resulting transgenic strain is then cleaved completely at the artificially inserted I-SpomI site(s) upon incubation with the I-SpomI restriction enzyme. The cleavage produces nested chromosomal fragments.
  • each artificially introduced I-SpomI site provides a unique “molecular milestone” in the genome.
  • a set of transgenic strains, each carrying a single I-SpomI site can be created which defines physical genomic intervals between the milestones. Consequently, an entire genome, a chromosome or any segment of interest can be mapped using artificially introduced I-SpomI restriction sites.
  • the nested chromosomal fragments may be transferred to a solid membrane and hybridized to a labeled probe containing DNA complementary to the DNA of the fragments. Based on the hybridization banding patterns that are observed, the eukaryotic genome may be mapped.
  • the set of transgenic strains with appropriate “milestones” is used as a reference to map any new gene or clone by direct hybridization.
  • a single break within a chromosome at an artificial I-SpomI site results in cell division arrest followed by death (only a few % of survival). Presence of an intact sequence homologous to the cut site results in repair and 100% cell survival.
  • a single break within a chromosome at an artificial I-SpomI site results in repair using the chromosome homolog and 100% cell survival. In both cases, repair of the induced double strand break results in loss of heterozygosity with deletion of the non homologous sequences flanking the cut and insertion of the non homologous sequences from the donor DNA molecule. Fairhead and Dujon. Mol. Gen. Genet. 240: 170-180 (1993).
  • I-SpomI enzyme can be accomplished by many techniques, including direct introduction of active enzyme (e.g., microinjection, electroporation, scrape-loading of protein) and expression of protein from an inducible or constitutive viral or plasmid vector (e.g., adenoviral or retroviral vector).
  • active enzyme e.g., microinjection, electroporation, scrape-loading of protein
  • inducible or constitutive viral or plasmid vector e.g., adenoviral or retroviral vector
  • the methods allow the production of an unlimited number of cells and cell lines in which various genes or mutants of a given gene can be inserted at the predetermined location defined by the previous integration of the I-SpomI site.
  • Such cells and cell lines are thus useful for screening procedures, for phenotypes, ligands, drugs and for reproducible expression at a very high level of recombinant retroviral vectors if the cell line is a transcomplementing cell line for retrovirus production.
  • I-SpomI site is heterozygous (present on only one of the two homologous chromosomes). They can be propagated as such and/or used to create transgenic animals.
  • homozygous transgenics (with I-SpomI sites at equivalent positions in the two homologous chromosomes) can be constructed by regular methods such as mating.
  • Homozygous cell lines can be isolated from such animals.
  • homozygous cell lines can be constructed from heterozygous cell lines by secondary transformation with appropriate DNA constructs. It is also understood that cell lines containing compensated heterozygous I-SpomI insertions at nearby sites in the same gene or in neighboring genes are part of this invention.
  • mice cells or equivalents from other vertebrates can be used.
  • Cells from invertebrates can also be used. Any plant cells that can be maintained in culture can also be used independently of whether they have ability to regenerate or not, or whether or not they have given rise to fertile plants.
  • the methods can also be used with transgenic animals.
  • Similar cell lines can also be used to produce proteins, metabolites or other compounds of biological or biotechnological interest using a transgene, a variety of promoters, regulators and/or structural genes.
  • the gene will be always inserted at the same localisation in the chromosome.
  • transgenic animals it makes possible to test the effect of multiple drugs, ligands, or medical proteins in a tissue-specific manner.
  • the I-SpomI recognition site and I-SpomI enzyme can also be used in combination with homologous recombination techniques, such as that disclosed in EP 0419621B1.
  • homologous recombination techniques such as that disclosed in EP 0419621B1.
  • insertion of the I-SpomI recognition site in the CFTR locus using homologous sequences flanking the CFTR gene in the genomic DNA can be done.
  • the I-SpomI site can be inserted by spontaneous gene replacement by double-crossing over (Le Mouellic et al., Proc. Natl. Acad. Sci. USA 87: 4712-4716, 1990).
  • the inserted sequences can be maintained in a heterozygous state or a homozygous stale.
  • homozygation can be induced, for example, in a tissue specific manner, by induction of I-SpomI expression from an inducible promoter.
  • the insertion of the I-SpomI recognition site into the genome by spontaneous homologous recombination can be achieved by the introduction of a plasmid construct containing the I-SpomI recognition site and a sequence sharing homologies with a chromosomal sequence in the targeted cell.
  • the input plasmid is constructed recombinantly with a chromosomal target. This recombination leads to a site-directed insertion of at least one I-SpomI recognition site into the chromosome.
  • the targeting construct can either be circular or linear and may contain one, two, or more parts of homologies with any sequence contained in the targeted cell.
  • the targeting mechanism can occur either by the insertion of the plasmid construct into the target (O type vectors) or by the replacement of a chromosomal sequence by a sequence containing the I-SpomI recognition site ( ⁇ L type vectors). See Valancius and Smithies, Mol. Cell Biol. 11: 4389-4397 (1991).
  • mice can be used to modify their genome in expressing the I-SpomI enzyme into their somatic cells or into their germ line.
  • gene therapy One application is gene therapy.
  • gene therapy include immunomodulation (i.e. changing range or expression of IL genes); replacement of defective genes; and excretion of proteins (i.e. expression of various secretory protein in organelles).
  • the present invention further embodies transgenic organisms, for example animals, where an I-SpomI restriction site is introduced into a locus of a genomic sequence or in a part of a cDNA corresponding to an exon of the gene.
  • Any gene of a genome (animals human, insect, or plant, etc.) in which an I-SpomI site is introduced can be targeted by a plasmid containing the sequence encoding the corresponding endonuclease.
  • Introduction of the I-SpomI site may be accomplished by homologous recombination.
  • any gene can be targeted to a specific location for expression.
  • Transgenic organisms can be used in screening methods.
  • I-SpomI Gene activation can be controlled by I-SpomI.
  • a I-SpomI recognition site can be introduced into transgenic mouse strains containing, under the control of the neuron specific enolase promoter (pNSE) (Forss-Petter et al., Neuron, 5:187-197 (1990)), a duplication of a part (e.g., 62 bp) of the nlsLacZ gene in tandem repeat, thus creating a loss of the function of the gene by the introduction of a stop codon into the open reading frame.
  • the expression of the I-SpomI enzyme in these mice can reactivate the recombination between the two tandem repeats leading to the reactivating of the gene in all of the central nervous system (CNS).
  • CNS central nervous system
  • the same experiment can be realized with the DT-A fragment of the dyphteric toxin leading to the genetic ablation of the entire CNS.
  • the genetic ablation can be performed by a tissue specific promoter or by the expression of the I-SpomI modified DT-A in a natural locus obtained by gene targeting.
  • I-SpomI I cleavage site is introduced between a duplication of a gene in tandem repeats, creating a loss of function.
  • Expression of the endonuclease I-SpomI can induce the cleavage between the two copies. The reparation by recombination is stimulated and results in a functional gene.
  • I-SpomI cleavage can be induced by I-SpomI cleavage.
  • Locus insertion can be obtained by integration of one at a specific location in the chromosome by “classical gene replacement.”
  • the cleavage of recognition sequence by I-SpomI endonuclease can be repaired by non-lethal translocations or by deletion followed by end-joining.
  • a deletion of a fragment of chromosome could also be obtained by insertion of two or more I-SpomI sites in flanking regions of a locus. The cleavage can be repaired by recombination and results in deletion of the complete region between the two sites.
  • I-SpomI being part of an evolutionarily conserved family of proteins, it is understood that all applications developed with I-SpomI can also be made with other endonucleases provided that their cleavage specificity is high enough to be able to be recognized as a unique site in genomes of complex organisms such as fungi, animals, or plants.
  • the endonucleases can be directly expressed from their natural genes.
  • artificial genes need to be constructed due to the variability of the genetic code in the cell compartments in which such enzymes are naturally encoded. Constructions and all series of manipulations performed with I-SpomI and its site can be easily transformed with other endonucleases.
  • I-SpomI can be substituted in applications with other enzymes, such as I-SceI.
  • I-SpomI can be used in combination with other enzymes, such as I-SceI, I-CreI, I-CeuI and I-DmoI. See, e.g., U.S. Pat. No. 5,474,896.
  • a recombinant chromosome or cell can be constructed containing one or more I-SpomI restriction site and one or more Group I intron encoded endonuclease site (e.g., I-SceI sites).
  • a transgenic mouse can be constructed containing one or more I-SpomI restriction site and one or more Group I intron encoded endonuclease site (e.g., I-SceI sites). The sites can be at the same or different chromosomal locations.
  • I-SpomI can be used in combination with other enzymes, such as I-SceI to promote in vivo recombination.
  • other enzymes such as I-SceI
  • I-SceI enzymes that promote in vivo recombination.
  • I-SceI enzymes that promote in vivo recombination.
  • an expression vector expressing I-SpomI and I-SceI, or two separate expression vectors expressing the enzymes the expression of both of these enzymes can be introduced into cells.
  • the expression of these enzymes allows double-stranded breaks to be introduced simultaneously or sequentially into different parts of a genome. This approach can be used, for example, to delete stretches of DNA or to facilitate multiple recombination events.
  • a plasmid containing the polynucleotide encoding the ORF I-SpomI enzyme has been deposited at Collection Nationale de Cultures de Microorganismes (CNCM), 25, Rue du Dondel Roux, 75724 Paris, Cedex 15, France on Mar. 6, 2001, under accession number I-2643 (reference identification: E. coli BL21 (DE3) pLysS/pSP003).
  • Plasmid pSP001 contains a fragment of 520 codons corresponding to the entire open reading frame from the initiator ATG-codon in cox1E1 to the internal stop codon in cox1I1b (primer SP001m: 5′-GCACGCATGTCATATGGTCTTGAGTTTA ATG AACTCTTG-3′ [SEQ ID NO:1], primer SP002m: 5′-GCGTAGATGGATCCAAGTGATACTTGATAGTGGTGG-3′ [SEQ ID NO:2]).
  • Plasmid pSP003 contains the shortest insert, covering the 304 codons located in loop 8 ( FIG.
  • the third plasmid pSP005 was constructed using primer SP005 with primer SP002m giving a product of 386 codons covering the total sequence of the cox1I1b ORF (primer SP005: 5′-GCATATTAGGATCC ATG TTAAAGCCGCAGACAAAATTG-3′ [SEQ ID NO:4] together with primer SP002m).
  • Each of the plasmids was transformed into expression host E. coli BL21 (DE3) pLysS (Novagen, Madison).
  • Plasmid pP3E5-2 (48) served as template to determine the I-SpomI cutting-site and for the activity tests.
  • This derivative of pUC18 contains a cloned mtDNA fragment of the cox1 sequence from the intronless strain P3(49).
  • Recombinant proteins were expressed using the T7 expression system provided by Novagen, Madison.
  • Cells were grown at 37° C. to an OD 600 of 0.6-0.8 before inducing the expression by adding isopropyl- ⁇ -D-thiogalactopyranoside (IPTG).
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • the cells were grown for another three hours to an OD 600 of 2.3-2.8, harvested, washed with water and stored in aliquots at ⁇ 70° C.
  • Disruption of the cells was performed by using a French press and subsequently the crude homogenate was centrifuged at 40000 ⁇ g for 45 min in a Beckman JA25.50 rotor. The supernatant was immediately decanted and loaded onto the 1 ml HiTrap chelating affinity column (Amersham Pharmacia Biotech, Little Chalfont), charged with Ni 2+ . Purification steps using the affinity column were carried out on an ⁇ kta Purifier (Amersham Pharmacia Biotech, Little Chalfont) ( FIG. 2 ). The elution buffer, in which the enzyme was present after the elution step was changed to 100 mM Diethanolamine pH9.0 by using Micro Bio-Spin size exclusion columns (Bio-Rad, Hercules). The protein was stored at ⁇ 20°C. after adding glycerol to a final volume of 50% and the protein concentration was determined using the Bio-Rad Bradford protein assay (Bio-Rad, Hercules).
  • an antibody against the His-tag, coupled to horseraddish peroxidase was diluted in the TBST-milk solution 1:4500 and the membrane was incubated for 1 h at 37° C. Then it was washed two times with TBST and once with PBS (50). Detection of the HRP-activity was carried out following the manual of the ECL-Kit (Amersham Pharmacia Biotech, Little Chalfont). Different samples were taken before or after the induction with IPTG (the crude homogenate, the lysed cells, the supernatant after centrifugation, the flow-through of peak and non-peak fractions). A sample of each of the first 15 fractions was loaded on a SDS-12% polyacrylamide gel and stained with Coomassie brilliant blue R250 to identify the fraction with the best ratio of expressed enzyme relative to other present proteins.
  • FIG. 2A A typical elution profile from a single purification step on a Ni-column is shown in FIG. 2A .
  • the protein peak always coelutes with a strong nucleic: acid signal.
  • the Bradford assay displayed a total protein concentration of 0.3 ⁇ g/ ⁇ l. With the major protein band at 38.7 kDa corresponding to about one third of the total, the concentration of I-SpomI could be estimated at circa 0.1 ⁇ g/ ⁇ l.
  • the preparation was stored in 100 mM Diethanolamine pH9.0/50% glycerol at ⁇ 20° C. and it was shown that these conditions kept the endonuclease activity stable for several months.
  • Plasmid pP3E5-2 (48), linearized with PstI, served as template for PCR to prepare DNA material to determine the cleavage site. The material was treated with Shrimp Alkaline Phosphatase and Exonuclease I to remove excess nucleotides and primers and then denatured. Prepared like this, the PCR-product w as used as template to generate a DNA sequencing ladder using cycle sequencing (Thermo Sequenase Cycle Sequencing Kit, USB, Miles Road) and 5′-end-labeled primer SP009 or SP008/SP010.
  • cycle sequencing Thermo Sequenase Cycle Sequencing Kit, USB, Miles Road
  • Digestion with I-SpomI was performed in a total reaction volume of 25 ⁇ l (6 ⁇ l endonuclease preparation, 100 mM Diethanolamine, pH9.0, 2.5 mM MgCl 2 , 1 ⁇ l of dissolved PCR product) at 37° C. for 10 min.
  • the reaction was terminated by the addition of 0.1 volumes of a 10 ⁇ stop solution (0.1 M Tris-HCl pH7.5, 0.25 M EDTA, 5% SDS, 0.5 mg/ml Proteinase K according to (51)) and incubated for 15 min to 50° C., and for 3 min up to 95° C. to inactivate the Proteinase K. Proteinase K was removed by phenol extraction and the sample precipitated.
  • the cleavage pattern of I-SpomI was determined by using 5′-end labeled PCR-products corresponding to the region flanking the intron insertion site in the continous, sequence of the cox1-gene of S. pombe strain P3 (44) as described under Materials and Methods. DNA was digested with I-SpomI and separated on a sequencing gel ( FIG. 3 ). Each DNA-strand shows a strong signal after cleavage with I-SpomI which is absent from uncleaved DNA. The cut position could be localized precisely by comparison with the sequencing ladder of the same DNA fragment.
  • a cut takes place 2 bp downstream of the intron insertion site on the sense strand and 2 bp for the lower strand generating 3′-overhangs of 4 nt.
  • This cleavage pattern is well known from other homing endonucleases. It has been reported for members of the dodecapeptide family like I-Crel (17), I-SceI (16) and II (37), I-CeuI (30) and I-DmoI (20) as well as for the His-Cys Box/ ⁇ -Me protein I-PpoI (53).
  • Substrates for I-SpomI were obtained by a PCR with primer SP009 and radioactive labeled primer SP008 as described in the preceding paragraph.
  • Standard conditions for the endonuclease cut were 100 mM Diethanolamine at pH9.0, 5 mM MgCl 2 , 100 mM NaCl, 1 ⁇ l of purified PCR-product in 15 ⁇ l water and finally 5 ⁇ l of prepared endonuclease in a total volume of 25 ⁇ l.
  • the reactions were incubated at 37° C. for 20 min.
  • MgCl 2 concentrations varied from 1 mM up to 40 mM
  • NaCl varied from 0 mM up to 200 mM.
  • the influence of temperature was monitored between 25° C.
  • pH-values ranged from pH6.0 (30 mM MES), pH7.0, pH8.0 (100 mM HEPES) and from pH9.0 to 10.0 (100 mM Diethanolamine). Reactions were stopped as mentioned before. They were separated on a 5% polyacrylamide/50% urea gel. After the run, the gel was soaked in a solution of 10% acetic acid/20% ethanol, put on Whatman 3 MM paper (Whatman, Maidstone) and dried. A Phosphor Imager screen (Molecular Dynamics, Sunnyvale) was exposed to the dried gel for 2.5 h at 25° C., results were quantified with the software mentioned before.
  • Known parameters that influence the activity of other homing endonucleases are the concentration of monovalent (Na + and K + ) and divalent cations (Mg 2+ and Mn 2+ ), temperature and proton concentration of the solution.
  • concentration of monovalent (Na + and K + ) and divalent cations (Mg 2+ and Mn 2+ ) concentration of monovalent (Na + and K + ) and divalent cations (Mg 2+ and Mn 2+ ), temperature and proton concentration of the solution.
  • a cleavage by I-SpomI should generate a smaller detectable band of 173 bp in length.
  • Mg 2+ is essential for the cutting capacity of I-SpomI as previously reported for all other known homing endonucleases. In the absence of Mg 2+ , no activity is detectable (not shown).
  • Optimal Mg 2+ concentration ranges from 5 mM to 7.5 mM ( FIG. 4A ). Lower or higher concentrations are disadvantageous for the enzyme activity. I-SpomI needs Na + but the tolerated concentration range is broad ( FIG. 4B ).
  • I-ScaI (43) optimal cleavage conditions have been reported as follows: Mg 2+ 8 mM, Na + about 50 mM, temperature between 28° C. and 40° C., pH between 8.5 and 9.0.
  • plasmids containing the nucleotide sequence from position ⁇ 13 to +12 around the insertion site of intron cox1I1b (see FIG. 5A ).
  • Complementary oligonucleotides were annealed in NEBuffer2 (New England Biolabs, Beverly) after denaturing the mix for 3 min at 95° C. and cooling it down slowly to 4° C. They were cloned into BamHI/HindIII-digested pUC19.
  • the recombinant plasmids were transformed via electroporation in E.coli strain DH10B and afterwards checked by EcoRV/XmnI-digestion of alkaline plasmid preparations (50).
  • DNA of recombinant plasmids was prepared from cultures of 40 ml LBA according to the QLAfilter tip 100 protocol (QIAGEN, Hilden). The concentration of the prepared plasmids was adjusted to 0.3 ⁇ g/ ⁇ l. Before exposing the plasmids to I-SpomI, they were digested with NdeI and AlwNI for 3 h at 37° C., subsequently treated for 20 min at 65° C., precipitated and dissolved in water to a final concentration of 0.1 ⁇ g/ml.
  • the I-SpomI-digest was carried out in a volume of 50 ⁇ l (250 ng DNA, 100 mM Diethanolamine pH9.6, 5 mM MgCl 2 , 100 mM NaCl, 5 ⁇ l I-SpomI). The digestion was terminated by adding 0.1 volumes stop solution (0.1M Tris-HCl pH7.5, 0.25M EDTA, 5% SDS) and incubating for 3 min at 65° C., followed by phenol-extraction and precipitation. Digested products were resuspended in 10 ⁇ l water and separated on a 0.8% agarose gel.
  • the gel was stained with 0.5 ⁇ g/ ⁇ l ethidium bromide after the run and the DNA was transferred via vacuum blot onto a Hybond-N + nylon membrane (Amersham Pharmacia Biotech, Little Chalfont). After transfer, the membrane was prehybridised for 1.5 h at 65° C. in hybridization buffer (0.25M phosphate buffer, 7% SDS, 1 mM EDTA, 1% BSA) and then hybridised overnight with random labeled pUC19 as probe (52). Incorporation of the label was determined in a 1 ⁇ l aliquot of the final probe preparation in a scintillation counter. After hybridization, the buffer containing the probe was removed, the membrane was washed with hybridization buffer at 65° C. and exposed to a Phosphor Imager screen (Molecular Dynamics, Sunnyvale) for 2.5 h at 25° C. and results were documented as mentioned before.
  • hybridization buffer 0.25M phosphate buffer, 7% SDS, 1 mM EDTA, 1% B
  • Nucleotides at positions ⁇ 11, ⁇ 10, ⁇ 8 to ⁇ 4, +2 to +6, +8 and +9 are essential for substrate recognition by I-SpomI. Transversion of the nucleotides at positions ⁇ 4 and +2 almost completely abolishes the cleavage. Changes in some nucleotides in the middle positions ⁇ 3 to +1, and at the borders of the sequence, positions ⁇ 9 and +7, have no effect on the recognition event. Thus the extent of the site is 20 bp in total. Within these 20 nucleotides, only 14 are essential for I-SpomI specificity.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
US10/933,476 2001-03-15 2004-09-03 Characterization of the I-SpomI endonuclease from fission yeast Abandoned US20060183129A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/933,476 US20060183129A1 (en) 2001-03-15 2004-09-03 Characterization of the I-SpomI endonuclease from fission yeast
US11/250,633 US7732194B2 (en) 2001-03-15 2005-10-17 Characterization of the I-SpomI endonuclease from fission yeast
US12/689,513 US8173429B2 (en) 2001-03-15 2010-01-19 Characterization of the I-Spomi endonuclease from fission yeast

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27563801P 2001-03-15 2001-03-15
PCT/EP2002/003357 WO2002074965A2 (en) 2001-03-15 2002-03-12 Characterization of the i-spoml endonuclease from fission yeast
US10/933,476 US20060183129A1 (en) 2001-03-15 2004-09-03 Characterization of the I-SpomI endonuclease from fission yeast

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10471723 Continuation 2002-03-12
PCT/EP2002/003357 Continuation WO2002074965A2 (en) 2001-03-15 2002-03-12 Characterization of the i-spoml endonuclease from fission yeast

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/250,633 Continuation US7732194B2 (en) 2001-03-15 2005-10-17 Characterization of the I-SpomI endonuclease from fission yeast

Publications (1)

Publication Number Publication Date
US20060183129A1 true US20060183129A1 (en) 2006-08-17

Family

ID=23053220

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/933,476 Abandoned US20060183129A1 (en) 2001-03-15 2004-09-03 Characterization of the I-SpomI endonuclease from fission yeast
US11/250,633 Expired - Fee Related US7732194B2 (en) 2001-03-15 2005-10-17 Characterization of the I-SpomI endonuclease from fission yeast
US12/689,513 Expired - Lifetime US8173429B2 (en) 2001-03-15 2010-01-19 Characterization of the I-Spomi endonuclease from fission yeast

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/250,633 Expired - Fee Related US7732194B2 (en) 2001-03-15 2005-10-17 Characterization of the I-SpomI endonuclease from fission yeast
US12/689,513 Expired - Lifetime US8173429B2 (en) 2001-03-15 2010-01-19 Characterization of the I-Spomi endonuclease from fission yeast

Country Status (6)

Country Link
US (3) US20060183129A1 (ja)
EP (1) EP1368481B1 (ja)
JP (3) JP4510379B2 (ja)
AU (1) AU2002246116B2 (ja)
CA (1) CA2440966C (ja)
WO (1) WO2002074965A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115176017A (zh) * 2019-10-25 2022-10-11 牛津大学创新有限公司 修饰的细胞

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246116B2 (en) * 2001-03-15 2007-02-15 Centre National De La Recherche Scientifique Characterization of the I-SpomL endonuclease from fission yeast
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
AU2002246116B2 (en) * 2001-03-15 2007-02-15 Centre National De La Recherche Scientifique Characterization of the I-SpomL endonuclease from fission yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115176017A (zh) * 2019-10-25 2022-10-11 牛津大学创新有限公司 修饰的细胞

Also Published As

Publication number Publication date
US8173429B2 (en) 2012-05-08
JP2004535164A (ja) 2004-11-25
CA2440966A1 (en) 2002-09-26
CA2440966C (en) 2014-09-16
AU2002246116C1 (en) 2002-10-03
US20100229253A1 (en) 2010-09-09
JP4756058B2 (ja) 2011-08-24
WO2002074965A3 (en) 2003-04-17
JP2008253273A (ja) 2008-10-23
WO2002074965A2 (en) 2002-09-26
EP1368481B1 (en) 2017-04-12
US7732194B2 (en) 2010-06-08
AU2002246116B2 (en) 2007-02-15
US20060286656A1 (en) 2006-12-21
JP2010162041A (ja) 2010-07-29
JP4510379B2 (ja) 2010-07-21
EP1368481A2 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
US10314297B2 (en) DNA knock-in system
KR102468108B1 (ko) 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
JP6688231B2 (ja) 標的遺伝子座を修飾するための方法及び組成物
US8426177B2 (en) Meganuclease variants cleaving a DNA target sequence from the mouse ROSA26 locus and uses thereof
JP5524627B2 (ja) 新規な基質特異性を有するｌａｇｌｉｄａｄｇホーミングエンドヌクレアーゼ変異型及びその使用
US20160145645A1 (en) Targeted integration
US20030232410A1 (en) Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
CA2678709A1 (en) Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
JP2013537410A (ja) 標的化エンドヌクレアーゼおよび一本鎖核酸を用いたゲノム編集
US8173429B2 (en) Characterization of the I-Spomi endonuclease from fission yeast
AU2002246116A1 (en) Characterization of the I-SpomL endonuclease from fission yeast
AU2007202165B2 (en) Characterization of the I-spoml endonuclease from fission yeast
WO2003066867A2 (en) Genetically engineered phic31-integrase genes
Shaw-White Analysis of chromosomal position-effects on gene expression in embryonic stem cells and their derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: INSTITUT PASTEUR,FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;SIGNING DATES FROM 20070105 TO 20070516;REEL/FRAME:019349/0477

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,FRANC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;SIGNING DATES FROM 20070105 TO 20070516;REEL/FRAME:019349/0477

Owner name: UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI),FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;SIGNING DATES FROM 20070105 TO 20070516;REEL/FRAME:019349/0477

Owner name: INSTITUT PASTEUR, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;REEL/FRAME:019349/0477;SIGNING DATES FROM 20070105 TO 20070516

Owner name: UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI), FRANC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;REEL/FRAME:019349/0477;SIGNING DATES FROM 20070105 TO 20070516

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLENZ, STEFAN;DUJON, BERNARD;HARINGTON, ALEXIS (DECEASED)/J.S. HARINGTON & E. DE WET (LEGAL REPRESENTATIVES);AND OTHERS;REEL/FRAME:019349/0477;SIGNING DATES FROM 20070105 TO 20070516